首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1378892

神經生物標記市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Neurological Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日期: 2023年11月02日 | 出版商:

IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

概要

2022年，全球神經生物標記市場規模達到79億美元。展望未來， IMARC Group預計到2028年市場規模將達到164億美元，2022-2028年複合年成長率（CAGR）為12.9%。

神經生物標記是存在於血液或腦脊髓液 (CSF) 中的分子，可支持腦部疾病的診斷和監測疾病進展。這些生物標記的主要來源是基因突變、代謝物水平、腦部影像以及蛋白質表現或翻譯後修飾的變化。由於神經生物標記檢測對實驗藥物的生物反應並有助於發現治療干預的新靶點，因此神經生物標記在藥物開發過程中廣泛應用於臨床實踐。目前，研究人員測量生物標記濃度，以提供非侵入性檢測、早期診斷和個人化治療。

中風、運動神經元疾病(MND)、阿茲海默症(AD)、帕金森氏症(PD) 和亨丁頓舞蹈症(HD) 等神經系統疾病的發生率不斷上升，對更快藥物開發的需求不斷增加。這是推動市場成長的主要因素之一，因為生物標記有助於衡量新藥和治療策略的療效。微創手術和個人化藥物的日益採用是另一個主要的成長誘導因素。除此之外，由於各種神經系統疾病具有共同的標準特徵，因此對多種生物標記來區分特定疾病及其亞型的需求不斷增加。此外，質譜和成像程序的進步使得能夠更快地評估大量生化標記物和大腦結構變化。隨著數位生物標記物的引入和臨床試驗數量的增加，預計將推動未來幾年市場的成長。

本報告回答的關鍵問題：

迄今為止，全球神經生物標記市場表現如何，未來幾年將如何表現？
COVID-19 對全球神經生物標記市場有何影響？
主要區域市場有哪些？
依類型分類市場是怎麼樣的？
基於應用程式的市場區隔是什麼？
根據最終用途分類的市場是怎樣的？
產業價值鏈的各個階段是什麼？
該行業的關鍵促進因素和挑戰是什麼？
全球神經生物標記市場的結構如何？誰是主要參與者？
產業競爭程度如何？

北美洲
- 美國
  - 市場走向
  - 市場預測
- 加拿大
  - 市場走向
  - 市場預測
亞太
- 中國
  - 市場走向
  - 市場預測
- 日本
  - 市場走向
  - 市場預測
- 印度
  - 市場走向
  - 市場預測
- 韓國
  - 市場走向
  - 市場預測
- 澳洲
  - 市場走向
  - 市場預測
- 印尼
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
歐洲
- 德國
  - 市場走向
  - 市場預測
- 法國
  - 市場走向
  - 市場預測
- 英國
  - 市場走向
  - 市場預測
- 義大利
  - 市場走向
  - 市場預測
- 西班牙
  - 市場走向
  - 市場預測
- 俄羅斯
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
拉丁美洲
- 巴西
  - 市場走向
  - 市場預測
- 墨西哥
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
中東和非洲
- 市場走向
- 按國家/地區分類的市場細分
- 市場預測

第 10 章：SWOT 分析

概述
優勢
弱點
機會
威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

概述
買家的議價能力
供應商的議價能力
競爭程度
新進入者的威脅
替代品的威脅

第 13 章：價格分析

第14章：競爭格局

市場結構
關鍵參與者
關鍵參與者簡介
- Abbott Laboratories
- Acumen Pharmaceuticals Inc.
- Athena Diagnostics (Quest Diagnostics)
- Banyan Biomarkers Inc.
- Bio-Rad Laboratories Inc.
- Immunarray Pvt. Ltd.
- Myriad Rbm Inc. (Myriad Genetics Inc.)
- Proteome Sciences Plc
- Thermo Fisher Scientific Inc.

簡介目錄圖表

Product Code: SR112023A3181

Abstract

The global neurological biomarkers market size reached US$ 7.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.4 Billion by 2028, exhibiting a growth rate (CAGR) of 12.9% during 2022-2028.

Neurological biomarkers are molecules present in the blood or cerebral spinal fluid (CSF) that support the diagnosis of brain disorders and monitor disease progression. The main sources of these biomarkers are genetic mutations, metabolite levels, brain imaging and changes in protein expression or post-translational modifications. As they detect biological responses to experimental drugs and aid in discovering new targets for therapeutic intervention, neurological biomarkers are widely used in clinical practice during drug development. Presently, researchers measure biomarker concentrations to provide non-invasive testing, earlier diagnosis and personalized treatments.

The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global neurological biomarkers market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, application and end use.

Breakup by Type:

Genomic Biomarkers

Proteomic Biomarkers

Metabolomic Biomarkers

Imaging Biomarkers

Others

Breakup by Application:

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Autism Spectrum Disorders

Others

Breakup by End Use:

Hospital Laboratories

Clinical Diagnostic Centers

Research Organizations

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Acumen Pharmaceuticals Inc., Athena Diagnostics (Quest Diagnostics), Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., Immunarray Pvt. Ltd., Myriad Rbm Inc. (Myriad Genetics Inc.), Proteome Sciences Plc and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

How has the global neurological biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global neurological biomarkers market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global neurological biomarkers market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Neurological Biomarkers Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Genomic Biomarkers
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Proteomic Biomarkers
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Metabolomic Biomarkers
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Imaging Biomarkers
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Application

7.1 Alzheimer's Disease
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Parkinson's Disease
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Multiple Sclerosis
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Autism Spectrum Disorders
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by End Use

8.1 Hospital Laboratories
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Clinical Diagnostic Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Research Organizations
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Acumen Pharmaceuticals Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
- 14.3.3 Athena Diagnostics (Quest Diagnostics)
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
- 14.3.4 Banyan Biomarkers Inc.
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 Bio-Rad Laboratories Inc.
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Immunarray Pvt. Ltd.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
- 14.3.7 Myriad Rbm Inc. (Myriad Genetics Inc.)
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
- 14.3.8 Proteome Sciences Plc
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Thermo Fisher Scientific Inc.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Neurological Biomarkers Market: Major Drivers and Challenges
Figure 2: Global: Neurological Biomarkers Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Neurological Biomarkers Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Neurological Biomarkers Market: Breakup by Type (in %), 2022
Figure 5: Global: Neurological Biomarkers Market: Breakup by Application (in %), 2022
Figure 6: Global: Neurological Biomarkers Market: Breakup by End Use (in %), 2022
Figure 7: Global: Neurological Biomarkers Market: Breakup by Region (in %), 2022
Figure 8: Global: Neurological Biomarkers (Genomic Biomarkers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Neurological Biomarkers (Genomic Biomarkers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Neurological Biomarkers (Proteomic Biomarkers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Neurological Biomarkers (Proteomic Biomarkers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Neurological Biomarkers (Imaging Biomarkers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Neurological Biomarkers (Imaging Biomarkers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Neurological Biomarkers (Alzheimer's Disease) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Neurological Biomarkers (Alzheimer's Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Neurological Biomarkers (Parkinson's Disease) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Neurological Biomarkers (Parkinson's Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Neurological Biomarkers (Multiple Sclerosis) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Neurological Biomarkers (Multiple Sclerosis) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Global: Neurological Biomarkers (Hospital Laboratories) Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Global: Neurological Biomarkers (Hospital Laboratories) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: Global: Neurological Biomarkers (Research Organizations) Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: Global: Neurological Biomarkers (Research Organizations) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: North America: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: North America: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: United States: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: United States: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: Canada: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: Canada: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Asia-Pacific: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Asia-Pacific: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: China: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: China: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Japan: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Japan: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: India: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: India: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: South Korea: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: South Korea: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: Australia: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: Australia: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Indonesia: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Indonesia: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Others: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Europe: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Europe: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Germany: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Germany: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: France: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: France: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: United Kingdom: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: United Kingdom: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Italy: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Italy: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Spain: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Spain: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Russia: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Russia: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Others: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 74: Latin America: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 75: Latin America: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 76: Brazil: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 77: Brazil: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 78: Mexico: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 79: Mexico: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 80: Others: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 81: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 82: Middle East and Africa: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
Figure 83: Middle East and Africa: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 84: Middle East and Africa: Neurological Biomarkers Market: Breakup by Country (in %), 2022
Figure 85: Global: Neurological Biomarkers Industry: SWOT Analysis
Figure 86: Global: Neurological Biomarkers Industry: Value Chain Analysis
Figure 87: Global: Neurological Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Neurological Biomarkers Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Neurological Biomarkers Market Forecast: Breakup by Type (in Million US$), 2023-2028
Table 3: Global: Neurological Biomarkers Market Forecast: Breakup by Application (in Million US$), 2023-2028
Table 4: Global: Neurological Biomarkers Market Forecast: Breakup by End Use (in Million US$), 2023-2028
Table 5: Global: Neurological Biomarkers Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Neurological Biomarkers Market: Competitive Structure
Table 7: Global: Neurological Biomarkers Market: Key Players

02-2729-4219

+886-2-2729-4219